RHOB and breast cancer: We studied the migratory and invasive capacity of different cell lines: the luminal breast cancer MCF7, and two basal-like cell lines: MDA-MB-231 with wild-type BRCA1, and HCC1937 with mutated BRCA1. RhoA and RhoB RNA silencing and Rho inhibitor (Rhosin) treatment were tested to evaluate their effect on migration and invasion.